(2R,4R)-1-[NG-nitro-N2-(3-methyl-8-quinolinesulphonyl)-L-arginyl]-4-methyl-2-piperidine carboxylic acid, CAS No. 74874-10-5

Welcome to iChemical.com!

In the below part, please select the country you want us to ship to: Please note that once you've selected a shipping country, all pricing information on our website will be automatically updated to include door-to-door shipping to the country you specified.

North America

South America

Africa

Europe

Asia

Oceania

74874-10-5

Catalog No. EBD55160

CAS 74874-10-5

Name (2R,4R)-1-[NG-nitro-N2-(3-methyl-8-quinolinesulphonyl)-L-arginyl]-4-methyl-2-piperidine carboxylic acid

Get Quote

Basic Information

Synonyms: (2R,4R)-1-[Nitroglycerine-nitro-N2-(3-methyl-8-quinolinesulfonyl (2R,4R)-1-[(2S)-5-[[Imino(nitroamino)methyl]amino]-2-[[(3-methyl-8-quinolinyl)sulfonyl]amino]-1-oxopentyl]-4-methyl-2-piperidinecarboxylicacid 2-piperidinecarboxylicacid,1-[5-[[imino(nitroamino)methyl]amino]-2-[[(3-methyl-8-quinolinyl)sufonyl]-1-oxopentyl]-4-methyl-,[2R-[1(S*),2α,4β]]- 2-piperidinecarboxylicacid,1-[5-[[imino(nitroamino)methyl]amino]-2-[[(3-methyl-8-quinolinyl)sulfonyl]amino]-1-oxopentyl]-4-methyl- 4-Methyl-1-{N2-[(3-methylquinolin-8-yl)sulfonyl]-N5-(N-nitrocarbamimidoyl)ornithyl}piperidine-2-carboxylicacid 4-methyl-1-[2-[(3-methyl-8-quinolyl)sulfonylamino]-5-[(N-nitrocarbamimidoyl)amino]pentanoyl]piperidine-2-carboxylicacid (2R,4R)-4-methyl-1-((s)-2-(3methylquinoline-8-sulfonamido)-5-(3-nitroguanidino)pentanoyl)piperidine-2-carboxylicacid 2-PiperidinecarboxylicAcid,1-[5-[Imino(Nitroamino)Methyl]Amino]-2-[[(3-Methyl-8-Quinolinyl)Sulfonyl]Amino]-1-Oxopentyl]-4-Methyl-,[2R-[1(S),2Alpha,4Beta]]-

Molecular Formula: C23H31N7O7S

Molecular Weight: 549.6

Categories: Medicinal Chemistry > APIs and Their Salts > Cardiovascular Drugs Medicinal Chemistry > Biochemicals and Life Science Reagents > Peptides and Peptidomimetics

Product Description:

This compound, with CAS number 74874-10-5, is a synthetic peptide derivative known as **Omapatrilat**. It is a potent, dual-acting vasopeptidase inhibitor designed to simultaneously inhibit both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). Its complex structure incorporates a modified amino acid sequence with a nitroguanidino group and a quinoline sulfonamide moiety, which are critical for its dual inhibitory activity. Omapatrilat was developed as an investigational antihypertensive and cardiovascular drug. By inhibiting ACE, it reduces the production of the vasoconstrictor angiotensin II, while its NEP inhibition increases levels of natriuretic peptides, promoting vasodilation, natriuresis, and diuresis. This dual mechanism was theorized to offer superior blood pressure control and potential benefits in heart failure compared to ACE inhibitors alone. Despite promising efficacy in clinical trials, its development was discontinued due to an increased incidence of angioedema, a serious side effect linked to its potent NEP inhibition.

Physical Properties

Boiling Point: 814.8 °C at 760 mmHg

Flash Point: 446.6 °C

Density: 1.53 g/cm3